ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,942.47
1.26%
US Tech 100
20,762.73
1.73%
Dow Jones
42,732.13
0.80%
Brent Oil
76.495
0.00%
Bitcoin
98,320.98
0.11%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSXV

  6. Aardvark 2 Capital Corp (ACCB.P) Quote

Aardvark 2 Capital Corp

Aardvark 2 Capital Corp (ACCB.P)

Aardvark 2 Capital Corp
0.09
0.00
(0.00%)
Closed January 05 4:00PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.09
Bid
0.05
Ask
0.15
Volume
-
0.00 Day's Range 0.00
0.09 52 Week Range 0.18
Market Cap
648k
Previous Close
0.09
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
7,200,000
Dividend Yield
-
PE Ratio
-8.33
Earnings Per Share (EPS)
-0.01
Revenue
7k
Net Profit
-78k

About Aardvark 2 Capital Corp

Sector
Copper Ores
Industry
Unit Inv Tr, Closed-end Mgmt
Headquarters
Toronto, Ontario, Can
Founded
2024
Aardvark 2 Capital Corp is listed in the Copper Ores sector of the TSX Venture Exchange with ticker ACCB.P. The last closing price for Aardvark 2 Capital was $0.09. Over the last year, Aardvark 2 Capital shares have traded in a share price range of $ 0.09 to $ 0.18.

Aardvark 2 Capital currently has 7,200,000 shares outstanding. The market capitalization of Aardvark 2 Capital is $648,000 . Aardvark 2 Capital has a price to earnings ratio (PE ratio) of -8.33.

Ask ADVFN Intelligence (AI)

ACCB.P Latest News

More News

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - ACCB.P

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - ACCB.P Canada NewsWire VANCOUVER, BC, le 14 juin 2024 VANCOUVER, BC, le 14 juin 2024...

June 14 2024
PR Newswire (Canada)

Canadian Investment Regulatory Organization Trading Halt - ACCB.P

Canadian Investment Regulatory Organization Trading Halt - ACCB.P Canada NewsWire VANCOUVER, BC, June 14, 2024 VANCOUVER, BC, June 14, 2024 /CNW/ - The following issues have been halted by...

June 14 2024
PR Newswire (Canada)

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - ACCB.P

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - ACCB.P Canada NewsWire VANCOUVER, BC, le 28 nov. 2023 VANCOUVER, BC, le 28 nov. 2023...

November 28 2023
PR Newswire (Canada)

Canadian Investment Regulatory Organization Trade Resumption - ACCB.P

Canadian Investment Regulatory Organization Trade Resumption - ACCB.P Canada NewsWire VANCOUVER, BC, Nov. 28, 2023 VANCOUVER, BC, Nov. 28, 2023 /CNW/ - Trading resumes in: Company: Aardvark 2...

November 28 2023
PR Newswire (Canada)

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - ACCB.P

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - ACCB.P Canada NewsWire VANCOUVER, BC, le 13 nov. 2023 VANCOUVER, BC, le 13 nov. 2023...

November 13 2023
PR Newswire (Canada)

Canadian Investment Regulatory Organization Trading Halt - ACCB.P

Canadian Investment Regulatory Organization Trading Halt - ACCB.P Canada NewsWire VANCOUVER, BC, Nov. 13, 2023 VANCOUVER, BC, Nov. 13, 2023 /CNW/ - The following issues have been halted by...

November 13 2023
PR Newswire (Canada)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1000.090.090.0900CS
4000.090.090.0900CS
12000.090.090.0900CS
26000.090.090.0900CS
52-0.01-100.10.180.092350.12671038CS
156-0.01-100.10.220.082150.12441992CS
260-0.01-100.10.220.082150.12441992CS

ACCB.P - Frequently Asked Questions (FAQ)

What is the current Aardvark 2 Capital share price?
The current share price of Aardvark 2 Capital is $ 0.09
How many Aardvark 2 Capital shares are in issue?
Aardvark 2 Capital has 7,200,000 shares in issue
What is the market cap of Aardvark 2 Capital?
The market capitalisation of Aardvark 2 Capital is CAD 648k
What is the 1 year trading range for Aardvark 2 Capital share price?
Aardvark 2 Capital has traded in the range of $ 0.09 to $ 0.18 during the past year
What is the PE ratio of Aardvark 2 Capital?
The price to earnings ratio of Aardvark 2 Capital is -8.33
What is the cash to sales ratio of Aardvark 2 Capital?
The cash to sales ratio of Aardvark 2 Capital is 90
What is the reporting currency for Aardvark 2 Capital?
Aardvark 2 Capital reports financial results in CAD
What is the latest annual turnover for Aardvark 2 Capital?
The latest annual turnover of Aardvark 2 Capital is CAD 7k
What is the latest annual profit for Aardvark 2 Capital?
The latest annual profit of Aardvark 2 Capital is CAD -78k
What is the registered address of Aardvark 2 Capital?
The registered address for Aardvark 2 Capital is 77 KING STREET WEST, SUITE 400, TORONTO, ONTARIO, M5K 0A1
Which industry sector does Aardvark 2 Capital operate in?
Aardvark 2 Capital operates in the UNIT INV TR, CLOSED-END MGMT sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MUST.HMust Capital Inc
$ 0.06
(200.00%)
165k
KUAI.PKua Investments Inc
$ 0.045
(125.00%)
14k
CRBKCarebook Technologies Inc
$ 0.095
(111.11%)
420.1k
CPLCopper Lake Resources Ltd
$ 0.01
(100.00%)
9k
VKG.HNorse Gold Corp
$ 0.02
(100.00%)
2.16k
TVITVI Pacific Inc
$ 0.005
(-50.00%)
11k
MTBMTB Metals Corp
$ 0.01
(-50.00%)
116.4k
ETUE2gold Inc
$ 0.005
(-50.00%)
10k
KOVOKovo+ Holdings Inc
$ 0.035
(-41.67%)
15k
PORPortofino Resources Inc
$ 0.01
(-33.33%)
349k
MATEBlockmate Ventures Inc
$ 0.41
(38.98%)
9.03M
DMDataMetrex AI Limited
$ 0.005
(0.00%)
4.48M
THRMTherma Bright Inc
$ 0.04
(14.29%)
3.45M
GPUSAlset AI Ventures Inc
$ 0.16
(-3.03%)
2.41M
SSESilver Spruce Resources Inc
$ 0.005
(0.00%)
2.14M

Discussion

View Full Feed
axelvento axelvento 6 minutes ago
Q1 the first interim analysis of the vaccine’s efficacy is expected

Moderna’s mRNA-1647
Cytomegalovirus
MRNA
MightyX MightyX 9 minutes ago
Yet no one is innocent
TPTW
BIG D 4 BIG D 4 10 minutes ago
WOW !! HAPPY NEW YEAR TO ALL THE LONGS HERE !! I HAVE 2 NAYSAYERS ON IGNORE SO I NEVER READ THEIR BS !! GO SAVING GRACE-- JJ AND ALL THE NEW POSTERS WHO ARE POSITIVE !! .02 CENTS TO START THE RUN TO ONE DOLLAR IS WHERE WE SHOULD BE !! THIS STOCK IS SUCH A GREAT BUY HERE !! I AM LOADED WITH 32 MILLI
MJNA
MightyX MightyX 10 minutes ago
The judicial system legitimizes prosecution
TPTW
jondoeuk jondoeuk 11 minutes ago
A new paper. From it: 'BNT221 was well tolerated across both DLs, with no dose-limiting toxicities of grade 3 or higher attributed to the T cell product observed. Specifically, no cytokine release, immune effector cell-associated neurotoxicity or macrophage activation syndromes were reported. A dose
BNTX
benz280c benz280c 12 minutes ago
Nice to see you are bullish. This quote may round out your knowledge.
"It is worthy to note that a new CUSIP has been approved by the CUSIP Global Services (CGS).
Subsequently, we have submitted a corporation action with FINRA for a Company name change, Ticker Symbol Change and Cusip
GDVM
shajandr shajandr 13 minutes ago
Sorry to read that you're still feeling sick. I posted a week or two ago about 41 bunnies and also some cats and dogs that were rescued from a home in Delaware county, Iowa and that were transferred to the DBQ county animal shelter. I just spoke with DaSqu_w and she went to the animal shelter to see
Lakota-45 Lakota-45 14 minutes ago
Will do, but I doubt they will listen !!!

~ Lol !!!
IONI
boi568 boi568 15 minutes ago
Probably
AVXL
HokieHead HokieHead 17 minutes ago
Wrong..
TWOH
HokieHead HokieHead 17 minutes ago
Get your facts straight, the halt was in the Canadian side as they are reviewing all the disclosures submitted, there’s ZERO issues in the US, it’s a fully reporting SEC company.
TWOH
Lakota-45 Lakota-45 19 minutes ago
I agree with you 'farmI1234 !!!

I'm pretty sure most of the Savvy Investors, that have been paying attention,
have been loading the dips, and .0004's, for a while now.
I know I have, along with fishing down stream.

I doubt any Longs will get caught short,
WDLF
CaptHowdy CaptHowdy 21 minutes ago
RECOMMENDED.... nothing is offical yet, unnecessary twisting of facts to bolster your negative viewpoints. Thats news is two months old
GRLT
axelvento axelvento 21 minutes ago
Cancer vaccines: What’s ahead in 2025

The spotlight is on mRNA-4157 (V940)

https://gulfnews.com/special-reports/cancer-vaccines-whats-ahead-in-2025-1.500010233
MRNA
facts_matter14 facts_matter14 22 minutes ago
Does this sound like a company with 16 products and a 17th on the way?

https://investorshub.advfn.com/uimage/uploads/2024/12/24/mwowsIMG_6034.png








.
SRMX
HomerRomer HomerRomer 22 minutes ago
More testimony videos from trial participants like the Australian news reel of Ern Heaven would be amazing. I would think that most of the people involved 9 years ago in the earlier phase studies have passed on since the average life expectancy is normally between 3-11 years after being diagnosed w
AVXL
CaptHowdy CaptHowdy 23 minutes ago
That's how to make money on the OTC. 🤦🏻‍♂️ Anyone could do it; only if the effort spent discounting the new leadership in place along with the turn around story underway was used to turn a profit vs. using 9yr old DD to bad mouth new CEO.
GRLT
crescentmotor crescentmotor 24 minutes ago
I think that is a bad precedent to start.

100% on parading a handful of Blarcamesine patients at the JPM conference. I highly doubt AVXL would involve itself with anecdotal gimmicks where there is no way possible to extrapolate isolated successes to meaningful conclusions about broad
AVXL JPM
Steady_T Steady_T 26 minutes ago
MABS are the current standard of care, so Blarcamesine has to be better than the MABS, which is not saying much.

I suspect that if Blarcamesine was the equal of the MABS is would still be approved on safety and cost grounds.

As has been pointed out multiple times on the
AVXL
facts_matter14 facts_matter14 27 minutes ago
Looks like Baggy is worried about Maxine not showing up at CES this week…………….









.
SRMX
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 28 minutes ago
Anavex has delayed PD in order to wait out the development of a reliable biomarker, which has happened only during the past few months.

OK so we should see the test start this quarter then?
AVXL
Canna_Business Canna_Business 28 minutes ago
$FKINX $IONQ $FFALX $MRMD $RKLB $XOM $DUK $LNVGY $V $SOFI $BICEY $VOO $TEMWX
BICEY DUK FFALX
mrfence mrfence 28 minutes ago
Actually, these issues traded on the NYSE under conservatorship and the FHFA made a decision to voluntarily delist Fannie and Freddie from the NYSE. There's Companies in bankruptcy like Gamestop, GME, trading on Big Boards. Unfortunately, the ball's in Gooberment's as to when they see fit to up lis
GME
Canna_Business Canna_Business 28 minutes ago
$FKINX $IONQ $FFALX $MRMD $RKLB $XOM $DUK $LNVGY $V $SOFI $BICEY $VOO $TEMWX
BICEY DUK FFALX

Your Recent History

TSXV
ACCB.P
Aardvark 2 Capital
DOWI
DWDVID
DJ Global Developed Indu...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads